CTRI/2009/091/001006已完成1 期
An open labeled, single dose, multiple escalation phase I/II study to evaluate the safety, tolerability and enhancement of tumor detection radiologically using VRP-1620 in patients with solid tumors. - VR-1620
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Female subjects in the age group of 18- 65 years
- •2.Subjects with biopsy breast cancer
- •3.Performance status, Karnofsky performance score >70
- •4.Patients have an ANC >1500, Platelets >100000
- •5.Subjects willing to give written informed consent.
排除标准
- •1.Patients with coagulopathy, history of stroke, deep vein thrombosis, cardiac dysfunction, uncontrolled hypertension, history of cardiac surgery, brain tumor or brain metastasis, and sarcomas
- •2.Patient with respiratory disorder
- •3.Pregnancy or lactation
- •4.Patients with abnormal renal & liver functions
- •5.Patients allergic to VRP-1620 and related products
研究者
相似试验
进行中（未招募）
1 期
Multi-center trial of FG001 in patients with malignant brain tumour scheduled for neurosurgery.MedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003089-38-SEFluoGuide A/S64
进行中（未招募）
1 期
FG001 in Glioblastoma Patients scheduled for NeurosurgeryMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003089-38-DKFluoGuide A/S64
尚未招募
1 期
To assess safety and efficacy of PNB028 in colon or pancreatic cancer patients.CTRI/2024/01/062125PNB Vesper Life Science Private Limited
撤回
1 期
A Study of JT001 Tablets in Caucasian Healthy Subjects after Oral AdministrationsCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000667718Shanghai Vinnerna BioSciences Co., Ltd27
进行中（未招募）
1 期
A Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant RecipientsPrevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865EUCTR2019-001730-34-GBSangamo Therapeutics France SAS30